Prognostic Utility of Serum Cystatin C/FT3 Ratio Combined with NT-proBNP in Patients with Heart Failure: A Retrospective Cohort Study

WANG Chuan He HAN Su TONG Fei LI Ying LI Zhi Chao SUN Zhi Jun

WANG Chuan He, HAN Su, TONG Fei, LI Ying, LI Zhi Chao, SUN Zhi Jun. Prognostic Utility of Serum Cystatin C/FT3 Ratio Combined with NT-proBNP in Patients with Heart Failure: A Retrospective Cohort Study[J]. Biomedical and Environmental Sciences, 2022, 35(5): 453-457. doi: 10.3967/bes2022.061
Citation: WANG Chuan He, HAN Su, TONG Fei, LI Ying, LI Zhi Chao, SUN Zhi Jun. Prognostic Utility of Serum Cystatin C/FT3 Ratio Combined with NT-proBNP in Patients with Heart Failure: A Retrospective Cohort Study[J]. Biomedical and Environmental Sciences, 2022, 35(5): 453-457. doi: 10.3967/bes2022.061

doi: 10.3967/bes2022.061

Prognostic Utility of Serum Cystatin C/FT3 Ratio Combined with NT-proBNP in Patients with Heart Failure: A Retrospective Cohort Study

Funds: This study was supported by a grant from the Science and Technology program of Liaoning Province [No. 2018225003]
More Information
    Author Bio:

    WANG Chuan He, male, born in 1987, Attending Physician, MD, majoring in the research of development of cardiovascular disease and heart failure

    Corresponding author: SUN Zhi Jun, Tel: 86-18940252598, E-mail: sunzj_99@163.com
  • S1.  Flow diagram for participant selection.

    S2.  Relative risk of all-cause (A) and cardiovascular (B) mortality stratified by tertiles of Cys-C/FT3 ratio and NT-proBNP level combination.

    S3.  Kaplan-Meier estimates of all-cause (A) and cardiovascular (B) mortality.

    Table  1.   Baseline clinical characteristics, median (IQR), or N (%), or means ± SD

    VariablesCys-C/FT31st tertileCys-C/FT32nd tertileCys-C/FT33rd tertileP-value
    N1,9701,9711,970
    Age (years)64.25 ± 13.6870.09 ± 13.1673.32 ± 12.16< 0.001
    Male 1,118 (56.8)1,094 (55.5)985 (50)< 0.001
    NYHA Fc< 0.001
     NYHA class II683 (34.7)363 (18.4)159 (8.1)
     NYHA class III787 (39.9)874 (44.3)769 (39.0)
     NYHA class IV500 (25.4)734 (37.2)1,042 (52.91)
    CHD1,201 (61.0)1,316 (66.8)1,381 (70.1)< 0.001
    Hypertension1,169 (59.3)1,224 (62.1)1,335 (67.8)< 0.001
    Diabetes mellitus552 (28.0)608 (30.8)830 (42.1)< 0.001
    Atrial fibrillation745 (37.8)659 (33.4)529 (26.9)< 0.001
    Previous MI298 (16.8)403 (20.4)453 (23.0)< 0.001
    COPD308 (21.1)297 (20.3)251 (17.6)0.042
    Stroke311 (15.8)353 (17.9)470 (23.9)< 0.001
    Current smoker591 (30.0)579 (29.4)517 (26.2)0.020
    Alcohol-related395 (20.1)371 (18.8)304 (15.4)< 0.001
    WBC (1012/L)7.17 ± 2.237.29 ± 2.407.75 ± 3.00< 0.001
    Hemoglobin (g/L)135.66 ± 17.71130.57 ± 19.03117.17 ± 24.17< 0.001
    Platelet (109/L)197.52 ± 61.43191.53 ± 62.94189.42 ± 81.450.001
    Albumin (g/L)39.01 ± 3.7137.37 ± 3.9635.09 ± 4.58< 0.001
    TC (mmol/L)4.13 ± 0.814.01 ± 0.754.02 ± 0.87< 0.001
    Triglycerides (mmol/L)1.37 ± 1.061.23 ± 0.871.32 ± 1.10< 0.001
    HbA1c (%)6.39 ± 1.256.59 ± 1.356.59 ± 1.270.002
    Cys-C (mg/L)1.02 ± 0.201.38 ± 0.242.37 ± 0.94< 0.001
    BUN (mmol/L)6.21 ± 1.987.44 ± 2.5212.63 ± 6.55< 0.001
    Creatinine (μmol/L )71.40 ± 17.6484.88 ± 23.17144.12 ± 77.85< 0.001
    Uric acid (μmol/L )380.89 ± 120.10432.36 ± 141.45526.09 ± 171.56< 0.001
    Potassium (mmol/L)3.97 ± 0.414.02 ± 0.464.25 ± 0.68< 0.001
    Sodium (mmol/L)139.93 ± 3.18139.05 ± 3.67137.87 ± 4.45< 0.001
    FT3 (pg/mL )2.63 ± 0.372.27 ± 0.361.87 ± 0.42< 0.001
    FT4 (pmol/L)14.22 ± 2.0014.45 ± 2.1514.21 ± 2.340.001
    TSH (mmol/L)1.56 (0.95, 2.46)1.58 (0.93, 2.49)1.61 (0.93, 2.53)0.957
    Troponin I (µg/L)0.02 (0.00, 0.05)0.03 (0.01, 0.08)0.05 (0.02, 0.17)< 0.001
    NT-proBNP (ng/L)1672.5 (660.1, 3499.0)3056.0 (1313.0, 6025.0)6869.8 (3057.0, 13666.8)< 0.001
    LVEDV (mL)156.81 ± 61.39162.40 ± 65.39160.86 ± 60.290.015
    LVESV (mL)83.01 ± 50.3589.41 ± 53.6189.32 ± 48.710.06
    LVEF (%)49.94 ± 12.2147.85 ± 12.1546.90 ± 12.79< 0.001
      Note. NYHA Fc, New York Heart Association cardiac function classification; CHD: coronary heart disease; Previous MI, previous myocardial infarction; COPD, chronic obstructive pulmonary disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; WBC, white blood cells; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; Cys-C, Cystatin C; BUN, blood urea nitrogen; FT3, free thyroxine 3; FT4, free thyroxine 4; TSH, thyroid stimulating hormone; NT-proBNP, N-terminal pro–B-type natriuretic peptide; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVEF, left ventricular ejection fraction.
    下载: 导出CSV

    Table  2.   Univariate and multivariate Cox regression analysis

    VariablesUnivariate analysisPMultivariate analysis*P
    Cys-C/FT3 ratio (per 1 increase)
     Cardiovascular mortality3.459 (3.164−3.782)< 0.0012.012 (1.594−2.538)< 0.001
     All-cause mortality3.510 (3.257−3.783)< 0.0011.866 (1.539−2.263)< 0.001
    Cys-C (per 1 increase)
     Cardiovascular mortality1.626 (1.560−1.696)< 0.0011.284 (1.156−1.426)< 0.001
     All-cause mortality1.643 (1.578−1.702)< 0.0011.291 (1.183−1.408)< 0.001
    FT3 (per 0.1 increase)
     Cardiovascular mortality0.526 (0.495−0.559)< 0.0010.809 (0.738−0.887)< 0.001
     All-cause mortality0.539 (0.512−0.567)< 0.0010.846 (0.783−0.913)< 0.001
    NT-proBNP (per 100 increase)
     Cardiovascular mortality1.008 (1.007−1.008)< 0.0011.003 (1.002−1.004)< 0.001
     All-cause mortality1.007 (1.006−1.007)< 0.0011.002 (1.002−1.003)< 0.001
      Note. *Adjusted for age, sex, NYHA Fc, coronary heart disease, hypertension, diabetes mellitus, atrial fibrillation, previous MI, chronic obstructive pulmonary disease, systolic blood pressure, diastolic blood pressure, heart rate, white blood cells, hemoglobin, platelets, albumin, low-density lipoprotein cholesterol, triglycerides, HbA1c, blood urea nitrogen, creatinine, uric acid, potassium, sodium, troponin I, LVEDV, LVESV, and LVEF. Cys-C, Cystatin C; FT3, free thyroxine 3; FT4, free thyroxine 4; NT-proBNP, N-terminal pro–B-type natriuretic peptide; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVEF, left ventricular ejection fraction. Cys-C, Cystatin C; BUN, blood urea nitrogen; FT3, free thyroxine 3; FT4, free thyroxine 4; NT-proBNP, N-terminal pro–B-type natriuretic peptide; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVEF, left ventricular ejection fraction
    下载: 导出CSV

    Table  3.   The C-statistic, discrimination, and reclassification

    VariablesC-statisticNRIIDI
    ZPNRIPIDIP
    All-cause mortality
     Cys-C/FT3+NT-rpoBNP vs. Cys-C/FT37.093< 0.010.4020.0260.0550.018
     Cys-C/FT3+NT-rpoBNP vs. NT-rpoBNP8.252< 0.010.4890.0140.0570.020
    Cardiovascular mortality
     Cys-C/FT3+NT-rpoBNP vs. Cys-C/FT32.770< 0.010.4020.0140.0550.014
     Cys-C/FT3+NT-rpoBNP vs. NT-rpoBNP3.769< 0.010.4890.0160.0570.032
      Note. NRI: net reclassification improvement; IDI: integrated discrimination improvement. Cys-C, Cystatin C; BUN, blood urea nitrogen; FT3, free thyroxine 3; FT4, free thyroxine 4
    下载: 导出CSV

    S1.   The AUC of the combination of the Cys-C/FT3 ratio and NT-proBNP level for clinical outcomes prediction

    Item HFHFrEFHFmrEFHFpEF
    In-hospital mortality
     Cardiovascular mortality0.779 (0.746−0.813)0.781 (0.714−0.847)0.751 (0.693−0.808)0.794 (0.739−0.849)
     All-cause mortality0.780 (0.749−0.811)0.784 (0.721−0.848)0.749 (0.695−0.802)0.800 (0.752−0.848)
    1-year mortality
     Cardiovascular mortality0.772 (0.754−0.789)0.741 (0.709−0.773)0.745 (0.711−0.779)0.787 (0.759−0.816)
     All-cause mortality0.767 (0.751−0.782)0.746 (0.716−0.777)0.735 (0.705−0.766)0.787 (0.763−0.811)
    3-year mortality
     Cardiovascular mortality0.729 (0.715−0.744)0.687 (0.659−0.715)0.706 (0.667−0.734)0.741 (0.718−0.765)
     All-cause mortality0.744 (0.731−0.757)0.713 (0.687−0.739)0.722 (0.696−0.748)0.757 (0.737−0.777)
    5-year mortality
     Cardiovascular mortality0.720 (0.706−0.734)0.675 (0.648−0.702)0.702 (0.674−0.730)0.726 (0.704−0.747)
     All-cause mortality0.740 (0.727−0.753)0.708 (0.682−0.733)0.726 (0.701−0.751)0.748 (0.730−0.767)
    8-year mortality
     Cardiovascular mortality0.714 (0.700−0.728)0.663 (0.635−0.690)0.695 (0.668−0.723)0.748 (0.729−0.766)
     All-cause mortality0.737 (0.724−0.749)0.698 (0.671−0.724)0.722 (0.697−0.747)0.756 (0.739−0.774)
    下载: 导出CSV
  • [1] Taylor CJ, Ordóñez-Mena JM, Roalfe AK, et al. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study. BMJ, 2019; 364, l223.
    [2] Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart, 2007; 93, 1137−46. doi:  10.1136/hrt.2003.025270
    [3] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC). Developed with the special contribution of the heart failure association (HFA) of the ESC. Eur J Heart Fail, 2016; 18, 891−975.
    [4] McMurray MD, Trivax JE, McCullough PA. Serum cystatin C, renal filtration function, and left ventricular remodeling. Circ Heart Fail, 2009; 2, 86−9. doi:  10.1161/CIRCHEARTFAILURE.109.856393
    [5] Correale M, Monaco I, Brunetti ND, et al. Redefining biomarkers in heart failure. Heart Fail Rev, 2018; 23, 237−53. doi:  10.1007/s10741-018-9683-2
    [6] Li X, Zhu H, Li P, et al. Serum cystatin C concentration as an independent marker for hypertensive left ventricular hypertrophy. J Geriatr Cardiol, 2013; 10, 286−90.
    [7] Dupont M, Wu YP, Hazen SL, et al. Cystatin C identifies patients with stable chronic heart failure at increased risk for adverse cardiovascular events. Circ Heart Fail, 2012; 5, 602−9. doi:  10.1161/CIRCHEARTFAILURE.112.966960
    [8] Maia AL, Goemann IM, Meyer ELS, et al. Deiodinases: the balance of thyroid hormone: type 1 iodothyronine deiodinase in human physiology and disease. J Endocrinol, 2011; 209, 283−97. doi:  10.1530/JOE-10-0481
    [9] Okayama D, Minami Y, Kataoka S, et al. Thyroid function on admission and outcome in patients hospitalized for acute decompensated heart failure. J Cardiol, 2015; 66, 205−11. doi:  10.1016/j.jjcc.2015.04.006
    [10] van der Molen AJ, Thomsen HS, Morcos SK. Effect of iodinated contrast media on thyroid function in adults. Eur Radiol, 2004; 14, 902−7. doi:  10.1007/s00330-004-2238-z
  • [1] Wen Deng, Ziyu Zhang, Xinxin Li, Yaqin Zhang, Weihua Cao, Shiyu Wang, Xin Wei, Zixuan Gao, Shuojie Wang, Linmei Yao, Lu Zhang, Hongxiao Hao, Xiaoxue Chen, Yuanjiao Gao, Wei Yi, Yao Xie, Minghui Li.  A Retrospective Study of Pregnancy and Fetal Outcomes in Mothers with Hepatitis C Viremia . Biomedical and Environmental Sciences, 2025, 38(7): 827-837. doi: 10.3967/bes2025.079
    [2] Liqun Liu, Zemin Cai, Xuewei Wang, Chunping Wang, Xiangyun Ma, Xianfeng Meng, Bofu Ning, Ning Li, Xia Wan.  A Case Study on Garbage Code Redistribution Methods for Heart Failure at City Level by Two Approaches . Biomedical and Environmental Sciences, 2025, 38(1): 119-125. doi: 10.3967/bes2024.173
    [3] HAN Su, WANG Chuan He, TONG Fei, LI Ying, LI Zhi Chao, SUN Zhao Qing, SUN Zhi Jun.  Shock Index, Modified Shock Index, and Age-Adjusted Shock Index in Predicting the In-Hospital Mortality in Patients with Heart Failure and Chronic Kidney Disease . Biomedical and Environmental Sciences, 2023, 36(3): 279-283. doi: 10.3967/bes2023.030
    [4] ZHANG Lei, GAI Xiao Yan, LI Xin, LIANG Ying, WANG Meng, ZHAO Fei Fan, ZHOU Qing Tao, SUN Yong Chang.  Influence of the Pre-shock State on the Prognosis of Medical Patients with Sepsis: A Retrospective Cohort Study . Biomedical and Environmental Sciences, 2023, 36(12): 1152-1161. doi: 10.3967/bes2023.150
    [5] LIU Bing, XIE Jia Yi.  The Value of Prealbumin and its Combination with NT-proBNP for Predicting in-hospital Mortality in Patients with Heart Failure: Real-World Research Based on Propensity Score Matching . Biomedical and Environmental Sciences, 2023, 36(11): 1090-1094. doi: 10.3967/bes2023.139
    [6] CHEN Lian, SHI Hui Feng, JIANG Hai, SHI Xiao Ming, WANG Yuan Yuan, ZHANG Ai Qing, CHONG Yi Wen, ZHAO Yang Yu.  Correlation of An Ultrasonic Scoring System and Intraoperative Blood Loss in Placenta Accreta Spectrum Disorders: A Retrospective Cohort Study . Biomedical and Environmental Sciences, 2021, 34(2): 163-169. doi: 10.3967/bes2021.022
    [7] ZHANG Jie, ZHANG Yin Fei, HU Chun Yan, ZHANG Yi, QI Hong Yan, LIN Lin, XU Yu, XU Min, LU Jie Li, BI Yu Fang, WANG Wei Qing, NING Guang, CHEN Yu Hong.  Serum Total Bilirubin and Risk of Progressing Diabetes: A Prospective Cohort Study . Biomedical and Environmental Sciences, 2021, 34(8): 632-636. doi: 10.3967/bes2021.087
    [8] ZHU Yuan Yue, ZHENG Rui Zhi, WANG Gui Xia, CHEN Li, SHI Li Xin, SU Qing, XU Min, XU Yu, CHEN Yu Hong, YU Xue Feng, YAN Li, WANG Tian Ge, ZHAO Zhi Yun, QIN Gui Jun, WAN Qin, CHEN Gang, GAO Zheng Nan, SHEN Fei Xia, LUO Zuo Jie, QIN Ying Fen, HUO Ya Nan, LI Qiang, YE Zhen, ZHANG Yin Fei, LIU Chao, WANG You Min, WU Sheng Li, YANG Tao, DENG Hua Cong, ZHAO Jia Jun, CHEN Lu Lu, MU Yi Ming, TANG Xu Lei, HU Ru Ying, WANG Wei Qing, NING Guang, LI Mian, LU Jie Li, BI Yu Fang.  Inverted U-Shaped Associations between Glycemic Indices and Serum Uric Acid Levels in the General Chinese Population: Findings from the China Cardiometabolic Disease and Cancer Cohort (4C) Study . Biomedical and Environmental Sciences, 2021, 34(1): 9-18. doi: 10.3967/bes2021.003
    [9] XUE Yuan, MAO Zhen Xing, LIU Xue, WEI Dan Dan, LIU Chang, PANG Shan Bin, YU Song Cheng, GAO Jiao Jiao, LIN Ji Song, ZHANG Dong Dong, WANG Chong Jian, LI Wen Jie, LI Xing.  Association of Serum Glucocorticoids with Various Blood Pressure Indices in Patients with Dysglycemia and Hypertension: the Henan Rural Cohort Study . Biomedical and Environmental Sciences, 2021, 34(12): 952-962. doi: 10.3967/bes2021.131
    [10] SAI Xiao Yong, GAO Feng, ZHANG Wen Yu, GAO Meng, YOU Jing, SONG Yu Jian, LUO Ting Gang, SUN Yuan Yuan.  Combined Effect of Smoking and Obesity on Coronary Heart Disease Mortality in Male Veterans: A 30-year Cohort Study . Biomedical and Environmental Sciences, 2021, 34(3): 184-191. doi: 10.3967/bes2021.012
    [11] WANG Guang Li, ZHANG Rui, ZHOU Yi Ting, WANG Ai Li, XU Tian, ZHANG Ming Zhi, LI Hong Mei, ZHANG Yong Hong.  Combined Effects of A Body Shape Index and Serum C-reactive Protein on Ischemic Stroke Incidence among Mongolians in China . Biomedical and Environmental Sciences, 2019, 32(3): 169-176. doi: 10.3967/bes2019.024
    [12] ZHANG Ce, WANG Dong, HOU Bing Jie, JIANG Lin, XU Lian Jun, TIAN Jian, ZHAO Yan Yan, ZHAO Xue Yan, FENG Xin Xing, ZHANG Yin, SUN Kai, XU Bo, ZHAO Wei, HUI Ru Tai, GAO Run Lin, LOU Hui Ling, YUAN Jin Qing, SONG Lei.  Prognostic Values of Serum Chloride and Sodium Levels in Patients with Three-vessel Disease . Biomedical and Environmental Sciences, 2019, 32(4): 250-259. doi: 10.3967/bes2019.035
    [13] TAN Shou Yong, LIANG Zhuo Zhi, Gift Chiwala, KUANG Hao Bin, HUANG Zhi Pei, QIN Hong Juan, LI Yan, LI Yan Qiong, Adnan Hameed H.M., ZHANG Tian Yu.  The Effects of Secondary Pneumonia on the Curative Efficacy of Multidrug-resistant Tuberculosis: A Retrospective Cohort Study . Biomedical and Environmental Sciences, 2018, 31(12): 908-912. doi: 10.3967/bes2018.123
    [14] MAO Gen Xiang, CAO Yong Bao, YANG Yan, CHEN Zhuo Mei, DONG Jian Hua, CHEN Sha Sha, WU Qing, LYU Xiao Ling, JIA Bing Bing, YAN Jing, WANG Guo Fu.  Additive Benefits of Twice Forest Bathing Trips in Elderly Patients with Chronic Heart Failure . Biomedical and Environmental Sciences, 2018, 31(2): 159-162. doi: 10.3967/bes2018.020
    [15] ZHAO Xue Yan, LI Jian Xin, TANG Xiao Fang, XU Jing Jing, SONG Ying, JIANG Lin, CHEN Jue, SONG Lei, GAO Li Jian, GAO Zhan, QIAO Shu Bin, YANG Yue Jin, GAO Run Lin, XU Bo, YUAN Jin Qing.  Prognostic Value of NT-proBNP in Stable Coronary Artery Disease in Chinese Patients after Percutaneous Coronary Intervention in the Drug-eluting Stent Era . Biomedical and Environmental Sciences, 2018, 31(12): 859-866. doi: 10.3967/bes2018.117
    [16] ZHU Zheng Bao, HUANGFU Xin Feng, ZHONG Chong Ke, ZHOU Yi Peng, TIAN Yun Fan, BUREN Batu, XU Tian, WANG Ai Li, LI Hong Mei, ZHANG Ming Zhi, ZHANG Yong Hong.  Combined Effects of Family History of Cardiovascular Disease and Serum C-reactive Protein Level on the Risk of Stroke:A 9.2-year Prospective Study among Mongolians in China . Biomedical and Environmental Sciences, 2017, 30(9): 632-640. doi: 10.3967/bes2017.084
    [17] ZHANG Xiao Guang, SHU Yao Gen, GAO Ju, WANG Xuan, LIU Li Peng, WANG Meng, CAO Yu Xi, ZENG Yi.  A New Method for Blood NT-proBNP Determination Based on a Near-infrared Point of Care Testing Device with High Sensitivity and Wide Scope . Biomedical and Environmental Sciences, 2017, 30(6): 426-431. doi: 10.3967/bes2017.056
    [18] TIAN Yun Fan, ZHOU Yi Peng, ZHONG Chong Ke, BUREN Batu, XU Tian, LI Hong Mei, ZHANG Ming Zhi, WANG Ai Li, ZHANG Yong Hong.  C-reactive Protein Level, Apolipoprotein B-to-apolipoprotein A-1 Ratio, and Risks of Ischemic Stroke and Coronary Heart Disease among Inner Mongolians in China . Biomedical and Environmental Sciences, 2016, 29(7): 467-474. doi: 10.3967/bes2016.062
    [19] MA Li, BAI Ya Na, PU Hong Quan, HE Jie, Bryan A.Bassig, DAI Min, ZHANG Ya Wei, ZHENG Tong Zhang, CHENG Ning.  A Retrospective Cohort Mortality Study in Jinchang, the Largest Nickel Production Enterprise in China . Biomedical and Environmental Sciences, 2014, 27(7): 567-571. doi: 10.3967/bes2014.088
    [20] ZHANG Bo, WANG Ping, ZHOU Quan, CHEN ChaoGang, ZHUO ShuYu, YE YanBin, HE QiQiang, CHEN YuMing, SU YiXiang.  The Relationships between Erythrocyte Membrane n-6 to n-3 Polyunsaturated Fatty Acids Ratio and Blood Lipids and C-reactive Protein in Chinese Adults: An Observational Study . Biomedical and Environmental Sciences, 2011, 24(3): 234-242. doi: 10.3967/0895-3988.2011.03.005
  • 21497Supplementary Materials.pdf
  • 加载中
图(3) / 表ll (4)
计量
  • 文章访问数:  786
  • HTML全文浏览量:  314
  • PDF下载量:  55
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-12-24
  • 录用日期:  2022-03-17
  • 网络出版日期:  2022-06-09
  • 刊出日期:  2022-05-20

Prognostic Utility of Serum Cystatin C/FT3 Ratio Combined with NT-proBNP in Patients with Heart Failure: A Retrospective Cohort Study

doi: 10.3967/bes2022.061
    基金项目:  This study was supported by a grant from the Science and Technology program of Liaoning Province [No. 2018225003]
    作者简介:

    WANG Chuan He, male, born in 1987, Attending Physician, MD, majoring in the research of development of cardiovascular disease and heart failure

    通讯作者: SUN Zhi Jun, Tel: 86-18940252598, E-mail: sunzj_99@163.com

English Abstract

WANG Chuan He, HAN Su, TONG Fei, LI Ying, LI Zhi Chao, SUN Zhi Jun. Prognostic Utility of Serum Cystatin C/FT3 Ratio Combined with NT-proBNP in Patients with Heart Failure: A Retrospective Cohort Study[J]. Biomedical and Environmental Sciences, 2022, 35(5): 453-457. doi: 10.3967/bes2022.061
Citation: WANG Chuan He, HAN Su, TONG Fei, LI Ying, LI Zhi Chao, SUN Zhi Jun. Prognostic Utility of Serum Cystatin C/FT3 Ratio Combined with NT-proBNP in Patients with Heart Failure: A Retrospective Cohort Study[J]. Biomedical and Environmental Sciences, 2022, 35(5): 453-457. doi: 10.3967/bes2022.061
  • Heart failure (HF) is a serious and advanced stage of heart disease that has remained a major public health threat despite advances in medical therapy. HF prevalence in developed countries is 1.5%–2.0% and significantly increases with age, with a reported HF prevalence of ≥ 10% in patients aged > 70 years[1]. Moreover, HF is associated with poor quality of life and has a five-year mortality rate of up to 50%[2]. HF is a complex syndrome involving different pathophysiological pathways (e.g., remodeling, myocardial injury, fibrosis, and inflammation), the components of which can be reflected by some biomarkers. The most used diagnostic and prognostic HF biomarker is the N-terminal B-type natriuretic peptide precursor (NT-proBNP) due to its longer plasma half-life and less biological variation compared to the B-type natriuretic peptide precursor (BNP)[3]. There has been extensive research on other biomarkers, including cystatin C (Cys-C) and free triiodothyronine (FT3), with prognostic value in patients with HF. When HF occurs, renal insufficiency activates the renin-angiotensin-aldosterone and sympathetic nervous systems, resulting in fluid retention, increasing cardiac preload, and aggravating pump failure. Cys-C is an early indicator of kidney injury that is involved in the pathological process of HF development. In patients with HF, chronic tissue hypoxia, gastrointestinal mucosal and liver congestion, and reduced protein intake and synthesis will lead to hypermetabolic thyroxine disorder, increasment of thyroxine receptor level, and inhibition of T4 transformation into T3, resulting in the increase of T3 clearance rate and decrease in plasma T3 level.

    Cys-C is not only an appropriate early biomarker of renal impairment, but also an inflammatory biomarker involved in the process of cardiac fibrosis in patients with HF. Cys-C can selectively inhibit cysteine protease activity, reduce elastic fiber degradation in cardiomyocytes, and increase myocardial collagen fiber destruction, which disturbs cardiac structure and function [4]. In addition, Cys-C may inhibit the degradation of tissue inhibitor of metalloproteinases-1 and osteopontin, promoting myocardial fibrosis and aggravating ventricular remodeling [5]. Clinically, plasma Cys-C levels are associated with left ventricular hypertrophy, diastolic dysfunction, and mortality in patients with HF [6]. Several studies have reported the prognostic value of baseline Cys-C levels with respect to rehospitalization and all-cause mortality in acute decompensated and chronic HF [7].

    Thyroid hormone abnormalities, including thyroid function hyperfunction, hypothyroidism, and low T3 syndrome, can influence the clinical manifestations and outcomes of cardiovascular disease. Among the thyroid hormones, FT3 and FT4 are more sensitive and clinically relevant than T3 and T4 since the former are the physiologically active forms of the latter [8]. Reduced FT3 levels are associated with increased cardiovascular morbidity and mortality (including for HF) [9]. There are several possible mechanisms underlying the influence of low FT3 levels on the prognosis of patients with HF. First, insufficient FT3 transformation causes increased oxidative stress damage of the endoplasmic reticulum and impaired adenosine triphosphate (ATP) utilization by cardiomyocytes, which results in myocardial fibrosis, ventricular remodeling, myocardial perfusion, and metabolic abnormalities, leading to impaired systolic function in patients with HF [10]. Second, there are specific T3 receptors in the myocardium. The low FT3 levels possibly decrease myocardial contractility and increase susceptibility to arrhythmia, which could cause death in patients with HF [9].

    In the present study, it was hypothesized that the Cys-C/FT3 ratio would be a useful prognostic predictor for the long-term outcome in HF patients and that combining this ratio with NT-proBNP would further improve risk stratification.

    Clinical data from patients with HF hospitalized in the Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, China between 2013 and 2018 were retrospectively collected. HF was diagnosed based on clinical signs and symptoms, echocardiography, and laboratory test results, as recommended by the 2016 ESC Guidelines [3]. Based on the cardiac function classification published by the New York Heart Association, heart function was categorized into levels II–IV. Furthermore, HF with reduced ejection fraction (HFrEF), mid-range left ventricular ejection fraction [LVEF] (HFmrEF), and preserved LVEF (HFpEF) was defined as having an LVEF of < 40%, ≥ 40% LVEF < 50%, and ≥ 50%, respectively. All patients were enrolled with informed consent, the study was approved by the Shengjing Hospital of China Medical University Ethics Committee and conducted according to the principles of the Declaration of Helsinki. The ethics approval number is 2019PS594K.

    In the retrospective cohort, all laboratory tests using fasting peripheral venous blood samples were performed on the day of admission or the morning after admission. The LVEF was determined through echocardiography using the biplane Simpson method within 3 days of admission. In December 2020, each patient’s survival status was investigated using the population death information registration management system of the Disease Control and Prevention Center of Liaoning Province. Additionally, cardiac and non-cardiac death was determined based on the International Classification of Diseases code of death diagnosis. In case information was unavailable in the system, data were obtained from the patients’ medical records, physicians, or relatives via telephone. Efforts were made to determine the nature of death in each case. The median follow-up duration was 3.2 (2–8) years.

    Normally and non-normally distributed quantitative variables were compared using one-way analysis of variance and the Mann-Whitney U-test, respectively, and expressed as the mean ± standard deviation and median (interquartile range), respectively. Categorical variables were compared using the chi-square test and presented as counts and proportions (%). The relationship between variables and survival was assessed using univariate and multivariate Cox regression models and reported as the hazard ratio (HR) [95% confidence interval (CI)]. C statistics were used to quantify the ability of the Cys-C/FT3 ratio to identify patients who died. Additionally, continuous net reclassification improvement (NRI) and integrated discrimination improvement (IDI) analyses were performed to assess the incremental prognostic value of the Cys-C/FT3 ratio. Effects of the Cys-C/FT3 ratio and NT-proBNP levels on survival were represented using the Kaplan-Meier curves. Comparisons were made using the log-rank test. The area under the receiver operating characteristic (AUROC) curve was used to determine whether the Cys-C/FT3 ratio in combination with the NT-proBNP level could predict cardiovascular and all-cause mortality in patients with HF with different types of LVEF. All tests were two-sided. Statistical significance was set at P < 0.05. Statistical analyses were performed using the SAS9.4 software (SAS Institute, Cary, N.C., USA).

    The study cohort included retrospective data for 7,563 HF patients hospitalized between January 2013 and December 2018. Those with acute myocardial infarction, severe anemia, renal failure, and severe infection were excluded from this study (Supplementary Figure S1, available in www.besjournal.com). The resulting cohort consisted of 5,911 patients, including 1,970 with a low Cys-C/FT3 ratio, 1,971 with a medium Cys-C/FT3 ratio, and 1,970 with a high Cys-C/FT3 ratio. Baseline patient characteristics and the occurrence of risk factors according to the Cys-C/FT3 ratio tertiles are shown in Table 1.

    Table 1.  Baseline clinical characteristics, median (IQR), or N (%), or means ± SD

    VariablesCys-C/FT31st tertileCys-C/FT32nd tertileCys-C/FT33rd tertileP-value
    N1,9701,9711,970
    Age (years)64.25 ± 13.6870.09 ± 13.1673.32 ± 12.16< 0.001
    Male 1,118 (56.8)1,094 (55.5)985 (50)< 0.001
    NYHA Fc< 0.001
     NYHA class II683 (34.7)363 (18.4)159 (8.1)
     NYHA class III787 (39.9)874 (44.3)769 (39.0)
     NYHA class IV500 (25.4)734 (37.2)1,042 (52.91)
    CHD1,201 (61.0)1,316 (66.8)1,381 (70.1)< 0.001
    Hypertension1,169 (59.3)1,224 (62.1)1,335 (67.8)< 0.001
    Diabetes mellitus552 (28.0)608 (30.8)830 (42.1)< 0.001
    Atrial fibrillation745 (37.8)659 (33.4)529 (26.9)< 0.001
    Previous MI298 (16.8)403 (20.4)453 (23.0)< 0.001
    COPD308 (21.1)297 (20.3)251 (17.6)0.042
    Stroke311 (15.8)353 (17.9)470 (23.9)< 0.001
    Current smoker591 (30.0)579 (29.4)517 (26.2)0.020
    Alcohol-related395 (20.1)371 (18.8)304 (15.4)< 0.001
    WBC (1012/L)7.17 ± 2.237.29 ± 2.407.75 ± 3.00< 0.001
    Hemoglobin (g/L)135.66 ± 17.71130.57 ± 19.03117.17 ± 24.17< 0.001
    Platelet (109/L)197.52 ± 61.43191.53 ± 62.94189.42 ± 81.450.001
    Albumin (g/L)39.01 ± 3.7137.37 ± 3.9635.09 ± 4.58< 0.001
    TC (mmol/L)4.13 ± 0.814.01 ± 0.754.02 ± 0.87< 0.001
    Triglycerides (mmol/L)1.37 ± 1.061.23 ± 0.871.32 ± 1.10< 0.001
    HbA1c (%)6.39 ± 1.256.59 ± 1.356.59 ± 1.270.002
    Cys-C (mg/L)1.02 ± 0.201.38 ± 0.242.37 ± 0.94< 0.001
    BUN (mmol/L)6.21 ± 1.987.44 ± 2.5212.63 ± 6.55< 0.001
    Creatinine (μmol/L )71.40 ± 17.6484.88 ± 23.17144.12 ± 77.85< 0.001
    Uric acid (μmol/L )380.89 ± 120.10432.36 ± 141.45526.09 ± 171.56< 0.001
    Potassium (mmol/L)3.97 ± 0.414.02 ± 0.464.25 ± 0.68< 0.001
    Sodium (mmol/L)139.93 ± 3.18139.05 ± 3.67137.87 ± 4.45< 0.001
    FT3 (pg/mL )2.63 ± 0.372.27 ± 0.361.87 ± 0.42< 0.001
    FT4 (pmol/L)14.22 ± 2.0014.45 ± 2.1514.21 ± 2.340.001
    TSH (mmol/L)1.56 (0.95, 2.46)1.58 (0.93, 2.49)1.61 (0.93, 2.53)0.957
    Troponin I (µg/L)0.02 (0.00, 0.05)0.03 (0.01, 0.08)0.05 (0.02, 0.17)< 0.001
    NT-proBNP (ng/L)1672.5 (660.1, 3499.0)3056.0 (1313.0, 6025.0)6869.8 (3057.0, 13666.8)< 0.001
    LVEDV (mL)156.81 ± 61.39162.40 ± 65.39160.86 ± 60.290.015
    LVESV (mL)83.01 ± 50.3589.41 ± 53.6189.32 ± 48.710.06
    LVEF (%)49.94 ± 12.2147.85 ± 12.1546.90 ± 12.79< 0.001
      Note. NYHA Fc, New York Heart Association cardiac function classification; CHD: coronary heart disease; Previous MI, previous myocardial infarction; COPD, chronic obstructive pulmonary disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; WBC, white blood cells; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; Cys-C, Cystatin C; BUN, blood urea nitrogen; FT3, free thyroxine 3; FT4, free thyroxine 4; TSH, thyroid stimulating hormone; NT-proBNP, N-terminal pro–B-type natriuretic peptide; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVEF, left ventricular ejection fraction.

    Figure S1.  Flow diagram for participant selection.

    In the final cohort, 2,651 (44.8%) patients with HF died [1,840 (31.1%) cases of cardiovascular death] over the course of a follow-up with a median duration of 3.2 years. Univariate Cox regression revealed a significant correlation of the Cys-C/FT3 ratio with survival [all-cause mortality HR: 3.510 (95% CI: 3.257–3.783)] and cardiovascular mortality [HR: 4.459 (95% CI, 3.164–3.782)]. After adjustment for demographic characteristics, patient history, and clinical characteristics in the multivariable model, the Cys-C/FT3 ratio remained a significant predictive factor for all-cause mortality [adjusted HR: 1.866 (95% CI: 1.539–2.263)] and cardiovascular mortality [adjusted HR: 2.012 (95% CI: 1.594–2.538)]. Moreover, NT-proBNP was significantly associated with all-cause and cardiovascular mortality (Table 2). Both univariate and multivariable Cox regression models demonstrated that all-cause and cardiovascular mortality in patients with HF were independently predicted by the Cys-C/FT3 ratio or NT-proBNP.

    Table 2.  Univariate and multivariate Cox regression analysis

    VariablesUnivariate analysisPMultivariate analysis*P
    Cys-C/FT3 ratio (per 1 increase)
     Cardiovascular mortality3.459 (3.164−3.782)< 0.0012.012 (1.594−2.538)< 0.001
     All-cause mortality3.510 (3.257−3.783)< 0.0011.866 (1.539−2.263)< 0.001
    Cys-C (per 1 increase)
     Cardiovascular mortality1.626 (1.560−1.696)< 0.0011.284 (1.156−1.426)< 0.001
     All-cause mortality1.643 (1.578−1.702)< 0.0011.291 (1.183−1.408)< 0.001
    FT3 (per 0.1 increase)
     Cardiovascular mortality0.526 (0.495−0.559)< 0.0010.809 (0.738−0.887)< 0.001
     All-cause mortality0.539 (0.512−0.567)< 0.0010.846 (0.783−0.913)< 0.001
    NT-proBNP (per 100 increase)
     Cardiovascular mortality1.008 (1.007−1.008)< 0.0011.003 (1.002−1.004)< 0.001
     All-cause mortality1.007 (1.006−1.007)< 0.0011.002 (1.002−1.003)< 0.001
      Note. *Adjusted for age, sex, NYHA Fc, coronary heart disease, hypertension, diabetes mellitus, atrial fibrillation, previous MI, chronic obstructive pulmonary disease, systolic blood pressure, diastolic blood pressure, heart rate, white blood cells, hemoglobin, platelets, albumin, low-density lipoprotein cholesterol, triglycerides, HbA1c, blood urea nitrogen, creatinine, uric acid, potassium, sodium, troponin I, LVEDV, LVESV, and LVEF. Cys-C, Cystatin C; FT3, free thyroxine 3; FT4, free thyroxine 4; NT-proBNP, N-terminal pro–B-type natriuretic peptide; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVEF, left ventricular ejection fraction. Cys-C, Cystatin C; BUN, blood urea nitrogen; FT3, free thyroxine 3; FT4, free thyroxine 4; NT-proBNP, N-terminal pro–B-type natriuretic peptide; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVEF, left ventricular ejection fraction

    The AUROC, NRI, and IDI revealed that the Cys-C/FT3 ratio allowed for a better prognostic prediction of the individual risk of all-cause and cardiovascular mortality in patients with HF when combined with the NT-proBNP levels (Table 3). Patients were stratified into nine groups according to the Cys-C/FT3 ratio and NT-proBNP level tertiles. Graduated increases in risk with respect to both markers were observed for those in the higher tertiles. The risk ratio for long-term all-cause mortality for patients with a high Cys-C/FT3 ratio in combination with high NT-proBNP levels was 7.7 times higher than for those with low levels and 9.22 times higher for cardiovascular mortality (Supplementary Figure S2, available in www.besjournal.com). Scores of 0, 1, or 2 were assigned to the Cys-C/FT3 ratio and NT-proBNP level tertiles. The minimum score was 0 and the maximum scores was 4 when the two markers’ scores were added. Supplementary Figure S3 (available in www.besjournal.com) shows the Kaplan-Meier survival curves for all-cause mortality according to the scores.

    Table 3.  The C-statistic, discrimination, and reclassification

    VariablesC-statisticNRIIDI
    ZPNRIPIDIP
    All-cause mortality
     Cys-C/FT3+NT-rpoBNP vs. Cys-C/FT37.093< 0.010.4020.0260.0550.018
     Cys-C/FT3+NT-rpoBNP vs. NT-rpoBNP8.252< 0.010.4890.0140.0570.020
    Cardiovascular mortality
     Cys-C/FT3+NT-rpoBNP vs. Cys-C/FT32.770< 0.010.4020.0140.0550.014
     Cys-C/FT3+NT-rpoBNP vs. NT-rpoBNP3.769< 0.010.4890.0160.0570.032
      Note. NRI: net reclassification improvement; IDI: integrated discrimination improvement. Cys-C, Cystatin C; BUN, blood urea nitrogen; FT3, free thyroxine 3; FT4, free thyroxine 4

    Figure S2.  Relative risk of all-cause (A) and cardiovascular (B) mortality stratified by tertiles of Cys-C/FT3 ratio and NT-proBNP level combination.

    Figure S3.  Kaplan-Meier estimates of all-cause (A) and cardiovascular (B) mortality.

    The AUCs for the combination of the Cys-C/FT3 ratio and NT-proBNP level for predicting all-cause mortality were 0.780, 0.767, 0.744, 0.740, and 0.737 for in-hospital, 1-, 3-, 5-, and 8-year mortality, respectively. The AUCs of the combination of the Cys-C/FT3 ratio and NT-proBNP level for predicting cardiovascular mortality were 0.779, 0.772, 0.729, 0.720, and 0.714 for in-hospital, 1-, 3-, 5-, and 8-year mortality, respectively (Supplementary Table S1, available in www.besjournal.com). In the subgroup analysis, the Cys-C/FT3 ratio in combination with NT-proBNP level had a greater discriminative ability for the mortality risk in patients with HFpEF than in patients with HFrEF. Most of the studies on predicting prognosis of patients with HF in recent decades have focused on individuals with HFrEF, while HFpEF appeared to have epidemiological and etiological characteristics that are different from HFrEF. The present study suggested that Cys-C/FT3 may be a valuable predictor for patients with HFpEF.

    Table S1.  The AUC of the combination of the Cys-C/FT3 ratio and NT-proBNP level for clinical outcomes prediction

    Item HFHFrEFHFmrEFHFpEF
    In-hospital mortality
     Cardiovascular mortality0.779 (0.746−0.813)0.781 (0.714−0.847)0.751 (0.693−0.808)0.794 (0.739−0.849)
     All-cause mortality0.780 (0.749−0.811)0.784 (0.721−0.848)0.749 (0.695−0.802)0.800 (0.752−0.848)
    1-year mortality
     Cardiovascular mortality0.772 (0.754−0.789)0.741 (0.709−0.773)0.745 (0.711−0.779)0.787 (0.759−0.816)
     All-cause mortality0.767 (0.751−0.782)0.746 (0.716−0.777)0.735 (0.705−0.766)0.787 (0.763−0.811)
    3-year mortality
     Cardiovascular mortality0.729 (0.715−0.744)0.687 (0.659−0.715)0.706 (0.667−0.734)0.741 (0.718−0.765)
     All-cause mortality0.744 (0.731−0.757)0.713 (0.687−0.739)0.722 (0.696−0.748)0.757 (0.737−0.777)
    5-year mortality
     Cardiovascular mortality0.720 (0.706−0.734)0.675 (0.648−0.702)0.702 (0.674−0.730)0.726 (0.704−0.747)
     All-cause mortality0.740 (0.727−0.753)0.708 (0.682−0.733)0.726 (0.701−0.751)0.748 (0.730−0.767)
    8-year mortality
     Cardiovascular mortality0.714 (0.700−0.728)0.663 (0.635−0.690)0.695 (0.668−0.723)0.748 (0.729−0.766)
     All-cause mortality0.737 (0.724−0.749)0.698 (0.671−0.724)0.722 (0.697−0.747)0.756 (0.739−0.774)

    There were a few limitations in the present study despite its large sample size. First, only the initially measured baseline levels of Cyst-C, FT3, and NT-proBNP without dynamic monitoring were used, which likely resulted in a bias in accuracy. Second, drug use among the included patients was not considered, which might have affected the study findings. The results confirmed that the Cys-C/FT3 ratio was a very valuable predictor for all-cause and cardiovascular mortality among patients with HF. Moreover, the Cys-C/FT3 ratio added prognostic information to that provided by the NT-proBNP level, especially in patients with HFpEF.

    Acknowledgements All of the authors who contributed towards this article met the criteria for authorship.

参考文献 (10)
补充材料:
21497Supplementary Materials.pdf

目录

    /

    返回文章
    返回